ALY-688 is under clinical development by Allysta Pharmaceuticals and currently in Phase III for Keratoconjunctivitis Sicca (Dry Eye). According to GlobalData, Phase III drugs for Keratoconjunctivitis Sicca (Dry Eye) have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how ALY-688’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ALY-688 (ADP-355) is under development for the treatment of dry eye disease. The drug candidate is administered through ophthalmic and subcutaneous route. The drug candidate is a synthetic peptide acts by targeting adiponectin receptor.
It was under development for obesity, chronic liver injury, liver fibrosis, breast cancer, scleroderma, lipodystrophy, nonalcoholic steatohepatitis and atherosclerosis.
Allysta Pharmaceuticals overview
Allysta Pharmaceuticals is a clinical stage biopharmaceutical company. The company ophthalmic solution activates adiponectin that signals pathways, it also develops small-molecule multi-kinase inhibitor to treat glaucoma, enabling healthcare providers to effectively treat glaucoma, ocular hypertension, and dry eye diseases. It is headquartered in Bellevue, Washington, United States.
For a complete picture of ALY-688’s drug-specific PTSR and LoA scores, buy the report here.